Following splenic injection, mice receiving pooled populations expressing wild-type Claudin-2 (Cldn2KO: WT, Cldn2KO: HA-WT) developed significant and comparable metastatic burden (Fig. 1b; Supplementary Fig. 3c, d), whereas the cohort injected with Cldn2KO: ΔPDZ BD expressing CRC cells exhibited reduced liver-metastatic burden (Supplementary Fig. 3c, d). This evidence concerns the gene CLDN2 and colorectal carcinoma.